Department of Electrical and Electronic Engineering, University of Hong Kong, Pokfulam, Hong Kong, China.
Ann N Y Acad Sci. 2010 Aug;1202:115-22. doi: 10.1111/j.1749-6632.2010.05587.x.
With transfusional iron overload, almost all the excess iron is sequestered intracellularly as rapidly mobilizable, dispersed, soluble ferritin iron, and as aggregated, insoluble hemosiderin iron for long-term storage. Established magnetic resonance imaging (MRI) indicators of tissue iron (R(2), R(2)*) are principally influenced by hemosiderin iron and change slowly, even with intensive iron chelation. Intracellular ferritin iron is evidently in equilibrium with the low-molecular-weight cytosolic iron pool that can change rapidly with iron chelation. We have developed a new MRI method to separately measure ferritin and hemosiderin iron, based on the non-monoexponential signal decay induced by aggregated iron in multiple-spin-echo sequences. We have initially validated the method in agarose phantoms and in human liver explants and shown the feasibility of its application in patients with thalassemia major. Measurement of tissue ferritin iron is a promising new means to rapidly evaluate the effectiveness of iron-chelating regimens.
在输血引起的铁过载中,几乎所有过量的铁都被隔离在细胞内,作为快速可移动的、弥散的、可溶性铁蛋白铁,以及作为长期储存的聚集的、不溶性的含铁血黄素铁。已建立的组织铁磁共振成像(MRI)指标(R2、R2*)主要受含铁血黄素铁的影响,变化缓慢,即使进行强化铁螯合治疗也是如此。细胞内铁蛋白铁显然与低分子量细胞溶质铁池处于平衡状态,铁螯合治疗可使其迅速变化。我们已经开发了一种新的 MRI 方法,该方法基于多自旋回波序列中聚集铁引起的非单指数信号衰减,可分别测量铁蛋白和含铁血黄素铁。我们最初在琼脂糖模型和人肝组织中验证了该方法,并证明了其在重型地中海贫血患者中应用的可行性。组织铁蛋白铁的测量是一种快速评估铁螯合治疗方案有效性的有前途的新方法。